Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178413 | 0.80 | — | — | |
| SCHEMBL2405510 | 0.78 | ALDH1A1 (0.42) | KDM1AMAOAMAOBIRAK4 | |
| SCHEMBL21422778 | 0.75 | ALDH1A1 (0.44) | KDM1AMAOAMAOBIRAK4 | |
| SCHEMBL28224591 | 0.72 | CYP1A2 (0.43) | POLBHPGDPKMMEN1HTT | |
| SCHEMBL129995 | 0.72 | — | — | |
| SCHEMBL5691374 | 0.72 | CYP1A2 (0.48) | OPRL1MEN1HTTKMT2ACYP1A2 | |
| SCHEMBL3167257 | 0.72 | CYP1A2 (0.58) | POLBHPGDPKMMEN1HTT | |
| SCHEMBL22570232 | 0.72 | IRAK4 (0.36) | KDM1AMAOAMAOBIRAK4 | |
| SCHEMBL1286686 | 0.72 | IRAK4 (0.36) | KDM1AMAOAMAOBIRAK4 | |
| SCHEMBL22570231 | 0.72 | KDM1A (0.34) | KDM1AMAOAMAOBIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | POLB 679/4885HPGD 1412/4885PKM 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.